NeoGenesis Capital Debuts Fund Backing Colossal Biosciences Spinouts

NeoGenesis Capital has launched its debut fund, and it will target spinouts from Colossal Biosciences, the company announced. The new vehicle marks the firm's first move into private equity investing.

The fund's strategy centers on companies spun out of Colossal Biosciences, the startup known for its work on de-extinction and genetic engineering. Rather than backing the parent company directly, NeoGenesis Capital wants to capture value from the ventures Colossal creates around its core technologies.

What do we know about the fund?

Details on the fund's size, close date and general partners weren't disclosed in the announcement. What's clear is the mandate: the debut vehicle exists to finance spinout companies emerging from the Colossal Biosciences ecosystem.

Colossal Biosciences has built its name on ambitious genetic engineering programs, including efforts to bring back extinct species. That research base has begun producing standalone ventures, and NeoGenesis Capital positions itself as a dedicated source of capital for them.

Why target spinouts rather than the parent?

Spinout-focused funds let investors buy into specific technologies at earlier valuations than the parent company commands. For a science-heavy platform like Colossal, spinouts also give individual programs their own cap tables, management and exit paths.

NeoGenesis Capital's launch signals that investors now see enough dealflow from the Colossal orbit to justify a dedicated vehicle. That's a notable vote of confidence in the commercialization pipeline around genetic engineering and synthetic biology.

What comes next?

Watch for the fund's first disclosed investments. Each spinout it backs will test whether Colossal's research platform can produce ventures that stand on their own commercially — and whether specialist funds like this one can carve out a niche financing them.